.Nature Medication, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of patients along with HER2+ innovative bosom cancer and also energetic or steady human brain metastases presented regular intracranial activity as well as systemic efficacy of T-DXd.